Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients by Niels Reinmuth et al.
Reinmuth et al. Respiratory Research 2013, 14:139
http://respiratory-research.com/content/14/1/139RESEARCH Open AccessTreatment and outcome of patients with
metastatic NSCLC: a retrospective institution
analysis of 493 patients
Niels Reinmuth1,4,5*†, Nadine Payer1†, Thomas Muley2,4, Hans Hoffmann2,4, Felix JF Herth3,4,
Matthias Villalobos1,4 and Michael Thomas1,4Abstract
Background: Most patients with metastatic non-small cell lung cancer (NSCLC) will face treatment with systemic
therapy. Current clinical studies are demonstrating improvements in chemotherapy and overall survival. However, it
remains unclear whether these results are translated into clinical practice.
Methods: We reviewed all stage IV NSCLC patients without second malignancies that were diagnosed from 2004
to 2006 at our institution. 493 consecutive patients were included into this retrospective analysis and were
followed-up until end of 2011.
Results: 352 patients (71.4%) received systemic therapy for up to 7 lines. For most patients, adjustments of dosages
or applications had to be made at some point of the treatment, but the total applied dose remained generally
close to the intended dose. The best disease control (BDC) rate decreased with increasing therapy lines from 59.7%
to about 35%. Patients with palliative local therapy but no systemic treatment demonstrated inferior survival
(median 2.9 versus 8.7 months, p < 0.001). The median interval between last treatment and death was 50 days and
15 days for chemotherapy and anti-EGFR therapy, respectively. BDC to the previous therapy lines was predictive for
improved BDC to third- but not second-line therapy. Performing multivariate analysis, BDC to previous therapy,
never-/ former-smoking status, and age > 70 years were associated with improved survival performing third-line therapy.
Conclusions: Stage IV NSCLC patients may receive substantial systemic therapy resulting in response and median
survival rates that are comparable to data from clinical studies. However, preselection factors are increasingly important
to improve therapy outcome and life quality.
Keywords: NSCLC, Chemotherapy, Therapy lines, Predictive factors, Palliative therapyBackground
Lung cancer remains the leading cause of cancer-related
deaths in the Western civilization with a median survival
of only 8 months for patients with stage IV non-small cell
lung cancer (NSCLC) treated with platinum-based therapy
[1,2]. In recent years, new developments in systemic ther-
apies have yielded extended survival, at least in large phase
III trials [3]. For example, the preselection of NSCLC* Correspondence: Nielsreinmuth@gmx.net
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stated.patients harboring EGFR mutations identified a sub-
group with improved response to both EGFR tyrosine
kinase inhibitors and chemotherapy. Also, the addition
of Bevacizumab to chemotherapy has led to favorable
response rates and extended overall survival [4]. Taking
these advances together, prolonged survival rates have been
described in large phase III studies compared to earlier
data [2]. However, it remains speculative whether highly
selective patient collectives as they are recruited to clinical
phase III studies represent the general population of lung
cancer patients in the daily routine, and whether the out-
come is comparable to data from clinical studies [5]. For
example, in a Veterans Affairs Central Cancer Registry
containing 20,511 NSCLC cancer patients from 2003 toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Reinmuth et al. Respiratory Research 2013, 14:139 Page 2 of 9
http://respiratory-research.com/content/14/1/1392008, guideline-recommended chemotherapy treatment
was received only by 34% of all metastatic patients aged
between 65 and 74 years [6]. This percentage was even
lower with increasing patient age. Moreover, the benefit of
chemotherapy beyond second-line treatment has only
been marginally addressed in clinical studies. Still, an in-
creasing subset of patients will receive more than two
therapy lines [7].
Since most metastatic NSCLC patients will inevitably
die of their disease, quality of life and integration of pallia-
tive care in the management of advanced cancers have re-
cently gained much attention. In a landmark study, Temel
and coworkers demonstrated a survival benefit for patients
assigned to early palliative care versus those in the stand-
ard care group [8]. Interestingly, both groups had compar-
able numbers of chemotherapy regimens while patients
assigned to early palliative care had a significantly longer
time between their last infusion dose and death [9]. How-
ever, data on intervals between last chemotherapy and
death from clinical practice is missing.
To address these questions, we reviewed metastatic
NSCLC patients diagnosed and treated in our institution
within a defined time interval with emphasis on delivered
chemotherapy treatment and potential prognostic factors
to identify patients most likely benefiting from subsequent
lines of systemic therapy.
Patients and methods
Using the hospital information system and medical re-
cords, we retrospectively reviewed all lung cancer patients
who were diagnosed at our institution between January
1st, 2004, and December 31st, 2006, and consented in
writing for analyses of their data. Patients with further ma-
lignancies including second primary lung cancers were ex-
cluded to avoid any bias due to different outcome [10].
Upon approval by the local Ethic Committee, patients and
their treating physicians were contacted, and the follow-
up statuses were completed (S-612/2012). NSCLC staging
was performed according to both the 6th and, retrospect-
ively, the 7th edition of the UICC criteria. The smoking
status was assessed at diagnosis of the lung cancer. Pa-
tients with total consumption of less than 100 cigarettes
were classified as neversmokers.
Systemic therapy
For each therapy line, the duration of therapy was calcu-
lated from the first to the last application day. The applied
dose compared to the intended dose was calculated for
each cycle and each therapy line. Delays of continuation of
systemic therapy of 3 or more days due to decelerated re-
covery or concurrent medical problems such as infections
were noted. Best response that was achieved at each ther-
apy line was assessed according to RECIST (v1.1) perform-
ing CT scans (usually every 2 cycles during therapy), andthe best disease control rate (BDCR) was calculated [11].
In general, application of chemotherapy was repeated every
3 weeks. For treatment with EGFR Tyrosine kinase inhibi-
tors (TKI), the duration of a therapy cycle was defined
as 4 weeks. All patients entered a follow-up program with
3-monthly visits for the first 2 years, 6-monthly visits after
2-5 years and yearly visits thereafter [12]. All follow-up
visits included physical examination, lung function tests
and a chest radiograph.
Statistical analysis
We scheduled December 31st, 2011 as the census date.
Survival was defined as interval between date of diagnosis
and death if not stated otherwise. Because of the nature of
this disease and the inability to ensure accuracy and
consistency across all patients due to the retrospective
character of this study, cause of death was not captured
but identified by clinical means. Survival analysis was
assessed using the Kaplan Meier method. Univariate ana-
lyses were done performing log rank regression tests.
Throughout, a p-value of <0.05 was considered to be statis-
tically significant. Multivariate analyses were performed
using stepwise multiple Cox regression (entry p = 0.05, exit
p = 0.10).
Results
A total of 493 patients with stage IV NSCLC were identi-
fied (Table 1). 57 (11.6%) patients (median age 72 years)
did not receive any anti-cancer treatment due to poor per-
formance status or upon patient denial. These patients
were characterized by a median survival of 1.3 months
(95%-CI 0.7-1.5 months). 352 patients (71.4%) received at
least one line of systemic treatment (Table 2). 84 patients
(17.0%) underwent only local treatment by surgery or
radiotherapy but had no systemic therapy due to the above
mentioned reasons. From diagnosis, these patients had
a median overall survival of 2.9 months (95%-CI 2.3-
3.6 months) that was significantly inferior to patients
treated with systemic therapy (median 8.7 months; 95%-
CI 7.6-9.8 months; p < 0.001; Figure 1).
Systemic therapy
352 patients with stage IV NSCLC received systemic ther-
apy which was given for up to 7 lines. The median age of
patients with systemic therapy was 62 years with 25.9% of
70 years or older. Cumulative numbers of therapy lines
were associated with improved survival but with decreasing
BDCRs (Table 3, Figure 2). Interestingly, even in higher
therapy lines, a BDCR of around 35% could be observed.
Using the 7th edition of UICC criteria, 14 patients would
be reclassified as having stage IIIB disease which did not
significantly alter the study results. In addition to systemic
therapy, a total of 213 patients (60.5%) received palliative
radiotherapy mainly due to symptomatic cerebral or bone




therapie (n = 436)
Patients with systemic
therapy (n = 352)
Patients with local
therapy only (n = 84)
Age at diagnosis (years)
Median 72 62 62 65
Range 50-84 34-86 34-86 44-85
< 70 years 22 (38.6) 321 (73.6) 261 (74.1) 60 (71.4)
≥ 70 years 35 (61.4) 115 (26.4) 91 (25.9) 24 (28.6)
Sex
Male 46 (80.7) 299 (68.6) 237 (67.3) 62 (73.8)
Female 11 (19.3) 137 (31.4) 115 (32.7) 22 (26.2)
Smoking status
Neversmoker 2 (4.8) 35 (9.9) 35 (12.5) 0 (0)
Former smoker 25 (59.5) 143 (40.5) 115 (40.9) 28 (38.9)
Current smoker 15 (35.7) 175 (49.6) 131 (46.6) 44 (61.1)
Unknown 15 83 71 12
Stage
Stage IV, UICC 6. edition 57 100 436 (100) 352 (100) 84 (100)
Stage IV, UICC 7. edition 56 (98.2) 419 (96.1) 338 (96.0) 81 (96.4)
Stage IIIB, UICC 7. edition 1 (1.8) 17 (3.9) 14 ( 4.0) 3 (3.6)
Histology
Adenocarcinoma 25 (43.9) 255 (58.5) 222 (63.1) 33 (39.3)
Squamous cell carcinoma 18 (31.6) 85 (19.5) 56 (15.9) 29 (34.5)
Large cell undifferentiated carcinoma 14 (24.6) 96 (22.0) 74 (21.0) 22 (26.2)
Percentages are displayed in brackets. Stage classification according to either 6th or 7th UICC edition. Because of rounding, not all percentages sum to 100.
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cal procedure with palliative intention including 17 resec-
tions of metastases (brain n = 5, skin n = 7, rip n = 2,
cervical lymph nodes n = 3), 12 pleurectomies, and 2 surgi-
cal drainages of pleural empyema. For 9 patients undergoing
palliative lung tumor resection (3 pneumonectomies, 1 bilo-
bectomy, 5 lobectomies), a median survival of 15.6 months
(95%-CI 0–12.3 months) was noted.Table 2 Therapy of all patients reflected in the
present analysis
Therapy modality n %
Patients receiving systemic therapy 352 71.4
Only Systemic therapy 122 24.7
Systemic therapy and radiotherapy 183 37.1
Systemic therapy and surgery 17 3.4
All therapy modalities 30 6.1
Patients receiving only local therapy 84 17.0
Only radiotherapy 67 13.6
Only surgery 5 1.0
Surgery and radiotherapy 12 2.5
Patients receiving no anti-cancer treatment 57 11.6
Figure 1 Overall survival of metastatic NSCLC patients. Patients
received either systemic therapy, palliative local treatment without
systemic therapy or no anti-cancer treatment. Median survival rates
were 8.7, 2.9, and 1.3 months respectively (p < 0.001).
Table 3 Application, response and survival of systemic therapy
Patients Response Overall survival
Lines of systemic therapy n % PR* SD* NE* PD* Median OS 95% CI
1 352 100 30.7 29.0 20.7 19.6 7.6 6.8-8.5
2 183 52.0 14.8 31.7 19.7 33.8 6.2 5.0-7.4
3 97 27.6 12.4 23.7 22.7 41.2 5.2 3.5-7.0
4 48 13.6 14.6 20.8 31.3 33.4 5.1 3.7-6.5
5 20 5.7 5.0 30.0 10 55.0 4.5 1.9-7.1
6 8 2.3 37.5 12.5 12.5 37.5 11.1 3.1-19.1
7 2 0.6 0 0 50 50
Survival is stated in months from the beginning of the respective line of systemic therapy. Response was assessed according to RECIST: PR, Partial response; SD,
stable disease; NE, not evaluable; PD, progressive disease. CI, confidence interval. OS, overall survival. * Because of rounding, not all percentages sum to 100.
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platinum-based combination therapy with gemcitabine as
the most frequent combination partner. For 145 patients
(which were younger than 70 years in 93.8%), cisplatin
was used. Due to toxicity, this treatment combination had
to be switched to carboplatin or continued as monother-
apy in 43 and 2 cases, respectively. Patients with initiation
of cisplatin based treatments had a similar BDCR (PR 40%
SD 32%) and overall survival (9.6 months; 95%-CI 7.8-
11.4 months) compared to patients treated with carbopla-
tin based combinations (PR 32%, SD 28%; median survival
10.5 months; 95%-CI 8.6-12.3 months). In contrast, pa-
tients treated with monotherapy had an inferior BDCR
(PR 9%, SD 25%) and a survival of 4.4 months (95%-CIFigure 2 Overall survival according to applied lines of systemic
therapy. Survival rates were calculated from date of diagnosis.
Median survival significantly improved with increasing numbers of
lines of systemic therapy (p < 0.001). Patients with 0–6 lines of
systemic treatment had a median survival of 2.0, 5.3, 8.7, 13.0, 14.1,
21.8, and 39.1 months, respectively.2.5-6.2 months; p < 0.001). Of 248 patients with platinum
based first-line chemotherapy not entering clinical studies,
157 patients (63.3%) experienced a dose reduction due to
toxicity. However, the applied mean dosage of all patients
compared to the intended dosage was only moderately re-
duced (Table 3). In contrast, first-line monotherapy could
be given only for a mean of 2.2 cycles and with an
intended dosage of 83%.
Subsequent therapy was applied largely as monotherapy
with docetaxel, pemetrexed, erlotinib and vinorelbine as
most frequent drugs. Similar to first-line therapy, the appli-
cation of subsequent lines had to be modified only to a
minor extent by delaying or reducing the dosage (Table 4).
Most frequent reasons for terminating the current therapy
were disease progression and worsening of health status.
The median treatment duration with EGFR TKI was
8 weeks (2–86 weeks) for second-line and 6 weeks (2–
78 weeks) for third-line treatment, respectively. Of note,
the response to second-line treatment with erlotinib (PR
15%, SD 30%) was comparable to docetaxel (PR12%, SD
29%). The median interval between last chemotherapy and
death was 50 days (266 patients; 95%-CI 40–60 days) while
the median time between stopping anti-EGFR therapy and
death was 15 days (68 patients; 95%-CI 10–20 days).
Predictive and prognostic factors of second- and
third-line therapy
A disease control as BDCR at previous systemic therapy
was predictive for a higher BDCR at third-line treatment
(Odds Ratio = 0.08; 95% CI 0.01-0.7; p = 0.047) but not for
improved BDCR at second-line therapy (p > 0.05). More-
over, age of 70 years or older was associated with im-
proved BDCR (Odds Ratio = 0.27; 95% CI 0.11-0.68; p =
0.005) at second-line therapy but not at third-line therapy.
After univariate analyses, prognostic factors for overall
survival from the initiation of second- and third-line ther-
apy are displayed in Table 5. For example, a history of dis-
ease control at previous systemic therapy significantly
correlated with favorable overall survival from second-
and third-line therapy. Similarly, patients with progressive
Table 4 Applied dosages and dose modifications of chemotherapy












% N N (%) N Days %
1st line
Platinum (n = 248) 96.1 3.9 47 (19.0)* 101 15 (3–52) 57.7
For combination therapy:
combined cytotoxic drug (n = 248)
84.1 3.9 146 (58.9)* 101 15 (3–52) 57.7
Monotherapy (n = 60) 82.9 2.2 31 (51.7) 13 14 (7–28) 91.6
2nd line
Monotherapy (n = 117) 95.4 3.2 20 (17.0) 26 15 (4–49) 77.7
EGFR-TKI (n = 41) ** 4.4 ** ** ** NA
Platinum-basedcombination (n = 18) NA 3.6 14 (77.8) 8 18 (4–31) 55.6
3rd line
Monotherapy (n = 49) 95.2 2.9 8 (16.3) 9 12 (7–24) 81.6
EGFR-TKI (n = 36) ** 3.4 ** ** ** NA
Platinum-basedcombination (n = 7) NA 3.3 4 (57.1) 3 12 (7–21) 71.4
Patients who entered clinical studies were excluded. EGFR TKI, tyrosine kinase inhibitor targeting the epidermal growth factor receptor. NA, not applicable.
*36 patients (14.5%) received a dose reduction of platinum and combined cytotoxic drug.
**no reliable data available.
Table 5 Univariate analysis of prognostic survival factors for 2nd and 3rd line therapy
Survival after 2nd line therapy Survival after 3rd line therapy
HR 95%-CI p-value HR 95%-CI p-value
Sex 0.120 0.415
Female 0.77 0.56-1.07 0.83 0.53-1.30
Male 1 1
Age 0.015 0.007
< 70 years 1 1
≥ 70 years 0.63 0.43-0.91 0.48 0.28-0.82
Smoking status* 0.032 0.012
Never smoker 0.56 0.34-0.93 0.43 0.21-0.86
Former smoker 0.69 0.48-0.99 0.53 0.32-0.87
Current smoker 1 1
Histology 0.037 0.597
Adenocarcinoma 0.59 0.40-0.88 0.89 0.46-1.7
Squamous cell carcinoma 0.64 0.38-1.09 1.19 0.53-2.63
Large cellundifferentiated carcinoma 1 1
Response to previous therapy line 0.001 < 0.001
Disease control 0.58 0.41-0.81 0.44 0.29-0.69
Progress 1 1
Response to both previous therapy lines NA < 0.001
Disease control in both previous lines ─ ─ 0.26 0.13-0.51
Disease control in any previous line ─ ─ 0.53 0.28-0.99
Progress in both previous lines ─ ─ 1
HR, hazard ratio; CI, confidence interval. *Patients with known smoking status.
“─” indicates that data could not be calculated.
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platinum-based chemotherapy had a significantly worse
survival after initiation of second-line treatment (p = 0.003
and p = 0.005, respectively; data not shown) which was par-
ticularly true for patients with adenocarcinoma (p = 0.05
and p = 0.032, respectively). Performing multivariate testing,
only age and tumor control at previous therapy lines
remained significant prognostic factors for both second-
and third-line therapy (Table 6).Complete resection of stage IV NSCLC disease
Tumor resection with curative intention was performed
on 16 patients including 7 pneumonectomies, 1 bilobect-
omy and 8 lobectomies. In addition, 9 and 7 patients
underwent resection of pulmonary and cerebral metasta-
ses, respectively. Moreover, 11 patients received radio-
therapy of the thorax (n = 4) and/or cerebrum (n = 9).
Deploying the new TNM stage classification, 2 patients
with ipsilateral pulmonary metastases would be reclassi-
fied as stage IIIB. All 16 patients with curative intended
surgery had a median survival of 13.6 months (95%-CI
0–33.2 months) with 2 patients being still alive after
5 years. Systemic therapy was applied to 9 patients who
had a median survival of 19.9 months (95%-CI 4.6-35.2).Table 6 Multivariate analysis of prognostic survival factors fo
Survival after 2nd lin
HR 95% CI
Age
< 70 years 1
≥ 70 years 0.61 0.41-0.89
Smoking status
Never smoker ─ ─
Former smoker ─ ─




Squamous cell carcinoma 0.61 0.35-1.05
Large cell undifferentiated carcinoma 1
Response to previous therapy line
Disease control 0.60 0.42-0.84
Progress 1
Response to both previous therapy lines
Disease control in both previous lines ─ ─
Disease control in any previous line ─ ─
Progress in both previous lines ─ ─
HR, hazard ratio; CI, confidence interval.
“─” indicates that data could not be calculated.Discussion
In recent years, few data on single institution experiences
regarding chemotherapy treatment of NSCLC patients has
been published, with the current analysis being one of
the largest collectives [13,14]. In general, results from large
phase III trials seem to be reproducible in the clinical
routine. With a response rate of 37% for first-line platinum-
containing regimens, our analysis demonstrated even im-
proved results compared to a large phase III study analyzing
four chemotherapy regimens (response rate 19%) [2] and
some newer studies (response rates of 28.2% and 21.6% for
cisplatin/gemcitabine combinations, respectively) [15,16].
Moreover, the median overall survival of our collective re-
ceiving first-line platinum-based chemotherapy was some-
what comparable to these studies reporting survival data
between 7.8 months [2] and 13.1 months [16]. As reported
in these studies, patients seemed to have recieved subse-
quent therapy to a comparable extent as in our study
[16,17]. Complete surgical resection of stage IV disease may
be an option for highly selected patients with stage IV dis-
ease [18,19]. However, the patient number in our study was
too small to draw any conclusions.
Similar to others [7,13], our data shows a decreasing
BDCR with progressing therapy-lines. Again, for second-
line therapy, our BDCR and survival rates somewhatr 2nd and 3rd line therapy
e therapy Survival after 3rd line therapy
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docetaxel, and erlotinib [17,20,21]. However, since we
could not retrospectively assess the performance status we
cannot exclude a possible influence of a poor performance
status on the outcome of advanced therapy lines. In our
study, all drugs used for therapy beyond first-line treat-
ment showed comparable outcome. For example, the re-
sponse rate of erlotinib was similar to docetaxel (15%
versus 12%). Again, this finding is in congruence with data
from previous studies with unselected patients regarding
the EGFR mutational status [17,22]. Few clinical studies
focusing on third-line therapy of NSCLC patients have
been conducted [20,21]. Importantly, the overall survival
rates after initiation of advanced therapy lines were super-
ior than the reported outcome of patients with best sup-
portive care alone after failure of first-line or second-line
chemotherapy [20,21].
The response to previous therapies may be both predict-
ive and prognostic for subsequent therapies. Due to small
patient numbers we analyzed BDCR rather than response
showing inconsistent results regarding its predictive value
for response in subsequent therapy lines which is similar
to previous studies [7,13,14]. Disease control with previous
therapies has been repetitively associated with improved
survival for subsequent chemotherapy which has been also
demonstrated in our analysis [7,13,23]. Moreover, patients
with progressive disease upon first-line chemotherapy
have been associated with poor prognosis in previous
studies with overall survival times around 5 months and
poor responses to subsequent therapy [24,25]. Interest-
ingly, in a recent phase III trial, patients with stage IV
adenocarcinoma and progressive disease within 9 months
of induction of first-line chemotherapy showed a signifi-
cant survival benefit with the addition of a multi-tyrosine
kinase inhibitor to second-line therapy with docetaxel
[26]. As analyzed for the first time in the current study,
this group was characterized by a significant worse prog-
nosis. Finally, patients aged 70 years or more showed im-
proved BDCR and overall survival for second-line therapy.
Interestingly, similar data has been reported for first-line
therapies [27]. However, several other studies do not sup-
port this finding [7,28] which may possibly be related to
high patient selection. Collectively, patients with advanced
NSCLC may most likely benefit from advanced therapy
lines when they experienced disease control after first-
and second-line treatments and have a favorable perform-
ance status [7].
Similar to other experiences, 50% of patients diagnosed
with metastatic NSCLC received more than 1 line of sys-
temic therapy and 30% of all patients were treated with 3
or more treatment lines [13,29]. Dose reductions and de-
lays of chemotherapy were a frequent necessity. However,
in the majority of patients, this led only to a modest re-
duction of the total applied dosage and minor delays. Inour analysis, the number of cycles was slightly lower as
observed in some clinical studies, likely due to higher se-
lection of patients entering clinical studies [15,17,20].
Patients that could not receive systemic therapy were
characterized by a much reduced median survival of
1.3 months which was even worse compared to earlier
clinical studies randomizing patients for best supportive
care only [5,30]. In contrast, patients treated with first-
line monochemotherapy had a slightly improved survival
which was still significantly lower compared to patients
treated with platinum-based combinations. Hence, while
we were not able to directly address the influence of co-
morbidities in our results, we agree that the health per-
formance status is a major prognostic factor regarding
survival and treatment options for patients with meta-
static NSCLC [31-33].
Importantly, the limited administration of systemic
therapy within the last months of the patient’s life has
been accepted as one parameter of measuring quality
of life [34]. In a clinical study, patients with metastatic
NSCLC treated with systemic therapy and early palliative
care had a significantly longer interval between last
chemotherapy dose and death than patients treated with
standard oncology care alone (median 64 vs 40.5 days;
p = 0.02). Interestingly, the former patients were charac-
terized by a significantly longer overall survival [8,9].
With a median of 50 days in our study, the interval be-
tween termination of systemic treatment and death was
somewhat longer compared to patients treated with
standard oncology care alone in this study [9] and com-
parable to other data [29]. Identifying the appropriate
time for ending systemic therapy and intensifying pallia-
tive care remain important challenges for improving on-
cologic treatment for our patients.
In summary, results from clinical studies are translated
into the clinical practice leading to increasing therapy
lines and advanced survival. Moreover, our analysis un-
derlines the importance of preselecting patients. Identifi-
cation of both predictive and prognostic factors as well
as the best time point of assessing these factors will be
critical to select patients who will most likely benefit
from intensified systemic therapy.
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